Damora Therapeutics, Inc. (NASDAQ: DMRA) has announced the appointment of Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Jarrett, who brings nearly three decades of experience in biotech, tech, and finance, previously served as Chief Operating Officer at Arcus Biosciences. In her new role, she will also join the company's Board of Directors. The Board expressed excitement about her appointment, highlighting her extensive background in oncology drug development and leadership in high-growth companies. Additionally, the company has appointed Cameron Turtle, D.Phil., and Michael Landsittel, M.B.A., to its Board of Directors. Turtle is currently the CEO of Spyre Therapeutics, while Landsittel has a strong background in finance, having served as CFO at Blueprint Medicines. The Board has also appointed Peter Harwin as Chairman. These leadership changes are expected to enhance Damora's strategic direction as it focuses on developing innovative therapies for blood disorders, particularly those driven by mutant calreticulin (mutCALR). The company aims to rapidly advance its lead program, DMR-001, and other pipeline assets to improve patient outcomes. The Board also acknowledged the contributions of departing directors Amit Munshi, Carl Goldfischer, and Jayson Dallas, emphasizing their leadership during significant company transitions. The changes in leadership and board composition are seen as a strategic move to position Damora for future growth and success in the competitive biotech landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.